The Academy of Military Medical Sciences (AMMS) of the People's Liberation Army Academy of Military Sciences (Chinese: 中国人民解放军军事科学院军事医学研究院) is a Chinese military medical research institute.[1][2] It was established in Shanghai in 1951.[3] It has been based in Beijing since 1958.
Academy of Military Medical Sciences | |||||||
---|---|---|---|---|---|---|---|
Simplified Chinese | 中国人民解放军军事科学院军事医学研究院 | ||||||
Traditional Chinese | 中國人民解放軍軍事科學院軍事醫學研究院 | ||||||
|
In October 2011, the drug "Night Eagle", developed to help soldiers cope with sleep deprivation during missions, was unveiled in an exhibition marking the institute's 60th anniversary.[4]
In December 2014, the Chinese government announced that the Academy of Military Medical Sciences had developed an Ebola virus vaccine candidate that had been approved for clinical trials.[1][2]
In December 2021, the United States Department of Commerce added the Academy of Military Medical Sciences to the Entity List, accusing it of aiding in the persecution of Uyghurs in China.[5]
COVID-19 vaccine
editDuring the COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop Convidecia. The development team, led by Chen Wei, registered a Phase 1 trial in March 2020 and a Phase 2 trial in April 2020.[6][7] It conducted its Phase III trials in Argentina,[8] Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia[13] with 40,000 participants.
In February 2021, global data from Phase III trials and 101 COVID cases showed the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[14] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[15][16] Convidecia is also similar to other viral vector vaccines like the Oxford–AstraZeneca vaccine and Sputnik V vaccine.[17] Its single-dose regimen and standard refrigerator storage requirement (2°to 8 °C) could make it a favorable vaccine option for many countries.[15]
Convidecia is approved for use by some countries in Asia,[18][19][20] Europe,[21][22] and Latin America.[23][24][25] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[26] Malaysia,[20] Mexico,[27] and Pakistan.[28]
The vaccine was the first one approved outside of clinical trials in an expedited decision, which authorized its use only by the Chinese military.[29]
See also
edit- Wu Dechang, radiation toxicologist and former President of AMMS
- JK-05
References
edit- ^ a b "China's Ebola vaccine enters clinical trials". Archived from the original on December 23, 2014. Retrieved 19 December 2014.
- ^ a b "China approves experimental Ebola vaccine for clinical trials". Reuters. 18 December 2014. Retrieved 19 December 2014.
- ^ Patti Waldmeir (October 15, 2014). "China sends thousands of doses of anti-Ebola drug to Africa". Financial Times.
- ^ "PLA eyes 'Night Eagle' to make army of night owls". South China Morning Post. 16 October 2011. Retrieved 5 January 2017.
- ^ Knutson, Jacob (December 16, 2021). "U.S. sanctions Chinese tech companies over abuse of Uyghurs". Axios. Retrieved December 16, 2021.
- ^ Xie, John (15 April 2020). "China Announces Phase 2 of Clinical Trials of COVID-19 Vaccine". Voice of America. Retrieved 18 April 2020.
- ^ "The Lancet: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response". EurekAlert!. 22 May 2020. Retrieved 24 December 2020.
- ^ "Comenzará en la Argentina un nuevo estudio de vacuna recombinante contra el SARS-CoV-2". infobae (in European Spanish). 14 December 2020. Retrieved 2020-12-15.
- ^ "Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health"". Government of Chile. Retrieved 2020-11-21.
- ^ "Chinese Covid vaccine trials to be expanded to five more states". Mexico News Daily. 2020-11-10. Retrieved 2020-11-11.
- ^ "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-10-21.
- ^ "Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax". Reuters. 2020-12-07. Archived from the original on December 7, 2020. Retrieved 2020-12-07.
- ^ Eltahir N (9 August 2020). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. Retrieved 9 August 2020.
- ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 2021-02-08.
- ^ a b "China's CanSino Covid Vaccine Shows 65.7% Efficacy". Bloomberg.com. 2021-02-08. Retrieved 2021-02-10.
- ^ "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that has 65% efficacy". Fortune. Retrieved 2021-02-11.
- ^ Zimmer C, Corum J, Wee SL (2020-06-10). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2020-12-12.
- ^ Liu, Roxanne (2021-02-25). "China approves two more domestic COVID-19 vaccines for public use". Reuters. Retrieved 2021-02-26.
- ^ "Pakistan purchases over 30 million COVID doses from China: sources". ARY NEWS. 2021-04-25. Retrieved 2021-04-26.
- ^ a b "Malaysia to receive CanSino vaccine this month | The Malaysian Insight". www.themalaysianinsight.com. Retrieved 2021-04-03.
- ^ Ashok, Rashmi (2021-03-22). "UPDATE 2-China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary". Reuters. Retrieved 2021-03-22.
- ^ "Membrii NITAG au venit cu recomandări privind utilizarea vaccinurilor împotriva COVID-19 în Republica Moldova". Ministerul Sănătății, Muncii și Protecţiei Sociale. 2021-03-03. Retrieved 2021-05-21.
- ^ "'Our gratitude always': From China's CanSino, Mexico welcomes biggest vaccine shipment yet". Reuters. 2021-02-11. Retrieved 2021-02-11.
- ^ "Argentina issues emergency approval to China's single-dose Cansino COVID-19 vaccine". Reuters. 2021-06-11. Retrieved 2021-06-11.
- ^ "ISP Approves Emergency Use And Importation Of Cansino Vaccine To Fight COVID-19". Institute of Public Health of Chile. Retrieved 2021-04-08.
- ^ "China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. Retrieved 2021-02-28.
- ^ Solomon, Daina Beth (2021-02-28). "China's CanSino says first vaccines packaged in Mexico will be ready in March". Reuters. Retrieved 2021-03-12.
- ^ "Pakistan develops homemade anti-Covid vaccine 'PakVac'". The Express Tribune. 2021-05-24. Retrieved 2021-05-25.
- ^ "CanSino's COVID-19 vaccine candidate approved for military use in China". Reuters. 2020-06-29. Retrieved 2020-12-13.